Financing Innovation - Early-stage companies are finding alternatives to venture capital. - BioPharm International

ADVERTISEMENT

Financing Innovation
Early-stage companies are finding alternatives to venture capital.


BioPharm International
Volume 26, Issue 4, pp. 24-26


G. Steven Burrill
In February 2012, Celgene made a strategic investment in Boston-based biotech Acetylon Pharmaceuticals, which was developing promising treatments for multiple myeloma and other diseases. The Big Biotech paid $15 million for preferred shares of Acetylon. The investment did not include any technology rights or license option rights. By then, the barely four-year-old startup had already raised $40 million to finance its programs without taking any money from traditional venture capital sources.

Acetylon was started in 2008 to build out a technology platform for a new class of selective histone deacetylase (HDAC) inhibitors that hold promise for causing tumor cell death without the severe side effects associated with the first class of HDACs on the market. Initial funding came from Marc Cohen, Acetylon's chairman and a trustee at Dana Farber Cancer Institute where the technology was developed. Along with some friends, he put up approximately $400,000 in seed capital to start the company and brought in Walter Ogier, Acetylon's president and CEO, as its only employee to run it.

By July 2009, Acetylon received $7.25 million from a group of angel investors, hired some staff, and advanced its research and development. When its lead drug candidate was ready for human testing, Acetylon turned to the Leukemia and Lymphoma Society, which is providing approximately $6 million in nondilutive, milestone-based, and conditionally repayable funding, representing half of the projected costs of the clinical trial. Acetylon went on to close a $27-million second round of financing from its existing venture philanthropists plus other private investors two months before the Celgene funding.

Acetylon's story is being played out among many life-sciences startups as they look for funding beyond traditional venture capital to angel investors, venture philanthropy, non-profit organizations, and foreign government funds looking for innovative technology to develop for their countries. In some cases, these other entities are filling the void left by venture capitalists that have moved away from early-stage financings.

Companies taking advantage of the different sources of capital led to a 22.8% increase in the total amount raised by privately held life sciences companies globally in 2012 to $12.4 billion compared with the $10.1 billion raised in 2011. Although many decry the lack of funding for early-stage life sciences companies, capital is available.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here